首页> 外文期刊>Research and practice in thrombosis and haemostasis. >Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors
【24h】

Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors

机译:抗凝血剂对纤维蛋白凝块结构的影响:维生素K拮抗剂与因子XA抑制剂的比较

获取原文
       

摘要

Background Abnormal clot structure has been identified in patients with thrombotic disorders. Anticoagulant therapy offers clear benefits for thrombosis prevention and treatment by reducing blood clot formation and size; nevertheless, there are limited data on the effects of different anticoagulants, where clotting is initiated with different triggers, on clot structure. Objectives Our aim was to investigate the effects of vitamin K antagonists and factor Xa inhibitors on clot structure. Methods Clots from pooled plasma spiked with rivaroxaban, apixaban, or enoxaparin, as well as plasma from patients on warfarin, were compared to plasma without anticoagulation. The kinetic profile of polymerizing clots was obtained by turbidity, fiber density was determined by confocal microscopy, clot pore size was investigated by permeation, and fiber size was analyzed using scanning electron microscopy. Clotting agonist was either tissue factor or thrombin. Results Following clotting with tissue factor, all anticoagulated clots had a significantly increased lag time, with the exception of enoxaparin. Rivaroxaban additionally led to significantly less dense and more permeable clots, with thicker fibers. In contrast, turbidity analysis following initiation with thrombin showed few effects of anticoagulation, with only enoxaparin leading to a prolonged lag time. Enoxaparin clots made with thrombin were less dense and more permeable. Conclusion Our results show that anticoagulants modulate clot structure particularly when induced by tissue factor, most likely due to reduction of thrombin generation. We propose that the effects of different anticoagulants could be assessed with a global clot structure measurement such as permeation or turbidity, providing information on clot phenotype.
机译:背景技术血栓紊乱患者已鉴定出异常凝块结构。通过减少血凝块形成和尺寸,抗凝治疗为血栓形成和治疗提供了明显的益处;然而,有关不同抗凝血剂的影响的数据有限,其中凝结在凝块结构上用不同的触发器启动。目的我们的目的是探讨维生素K拮抗剂和因子XA抑制剂对凝块结构的影响。方法与柠檬胺,甲苯甲烷类,Apixaban或亚诺帕林一起掺入的粘合等离子体,以及来自华法林患者的血浆,与血浆相比,血浆没有抗凝血。通过浊度,通过共聚焦显微镜测定纤维密度,通过渗透研究纤维密度,通过渗透研究凝结孔径,使用扫描电子显微镜分析纤维尺寸。凝血剂是组织因子或凝血酶。结果凝结组织因子后,所有抗凝凝块都具有显着增加的滞后时间,除烯脱蒿外。 Rivaroxaban另外导致厚度较小,更渗透的凝块,具有较厚的纤维。相反,在用凝血酶开始后的浊度分析表明抗凝凝血的影响很少,只有亚诺帕林导致延长的滞后时间。用凝血酶制成的烯脱蒿素凝块较少,更密集,更渗透。结论我们的研究结果表明,抗凝血剂特别是当由组织因子诱导时调节凝块结构,很可能是由于降低凝血酶产生。我们提出可以通过全局凝结结构测量来评估不同抗凝血剂的影响,例如渗透或浊度,提供有关凝块表型的信息。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号